Research output per year
Research output per year
Personal profile
Overview
Professor of Targeted Therapy and Oncology, University of Manchester and Honorary Consultant in Clinical Oncology at Christie Hospital NHS Foundation Trust
My collaborations
Senior Lecturer
Dr Jamie Honeychurch
Post-doctoral Research Scientists
Dr Eleanor Cheadle
Dr Urszula Cytlak
Dr Debayan Mukherjee
Dr Erminia Romano
Dr Ana Vitlic
Dr Xiaomeng Wang
Clinical Fellow PhD Student
Dr Shuhui Cheng
PhD Students
Victoria Smith
Nabina Pun
Olivia Steel
Sotia Zenios
Research interests
Radiotherapy (RT) is a highly effective tumouricidal cancer treatment delivered to around 50-60% of all cancer patients. However the potent immunomodulatory properties of RT have only recently been investigated. RT can induce a variety of immunogenic and phenotypic changes in the tumour cells and recalibrate the immune contexture of the tumour microenvironment . If the immunoregulatory effects of RT could be exploited there is the potential to significantly increase the anti-cancer effect of RT.
The recent major breakthrough of the immune checkpoint inhibitors (ICI) anti-CTLA-4 (cytotoxic T-Lymphocyte-associated protein 4) and anti-PD-1/PD-L1 (programmed death-ligand 1) has led to durable remissions and improved survival in a number of incurable metastatic cancers. This remarkable clinical efficacy has established immunotherapy as another effective form of cancer therapy and stimulated the “immunotherapy revolution” leading to the large scale development of a new class of therapeutics termed immuno-oncology (IO) agents. Despite this excitement surrounding IO agents, currently only the minority of patients respond to immune checkpoint inhibition with anti-PD-1 monoclonal antibody (mAb) and combination approaches are being explored to increase response rates.
Given that both RT and IO agents can enhance anti-tumour immunity, this provides a sound rationale for the development of RT and IO combination strategies which have the potential to transform the management of cancer and substantially increase the efficacy of RT. However rapid successful clinical translation of RT and IO combinations requires preclinical experimentation to inform clinical trial design by increasing the chances of delivering clinical effectiveness and thus reducing the time taken to achieve the goal of improved outcomes. Our current programme of research aims to address some of the most important questions regarding the potential of translating RT and IO agent combinations to improve cancer outcomes
Teaching
APEP
SSC
MRes Oncology
BSc Pathology course
Memberships of committees and professional bodies
Fellow of Royal College of Radiologists
Fellow of Royal College of Physicians (Edinburgh)
Fellow of Royal College of Pathologists
Methodological knowledge
Tumour immunology
anti-cancer antibodies
radiobiology
Qualifications
BSc, PhD, MB BS, DRCOG, FRCP, FRCR, FRCPath
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
CRUK science commitee
1 Sept 2018 → …
Research Beacons, Institutes and Platforms
- Lydia Becker Institute
- Manchester Cancer Research Centre
Keywords
- Cancer, immunology, lymphoma, antibodies, immunotherapy, radiotherapy
Fingerprint
Dive into the research topics where Timothy Illidge is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CCR2-driven monocyte recruitment is protective against radiotherapy-induced intestinal toxicity
Pun, N., Cytlak, U. M., Lee, D., Domingues, R. G., Cheadle, E. J., Forster, D., Williams, K. J., Graham, G., Hepworth, M. R., Travis, M. A., Illidge, T. M. & Dyer, D., 8 Nov 2024, Cold Spring Harbor Laboratory Press, (bioRxiv).Research output: Preprint/Working paper › Preprint
-
Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer
Smith, V., Lee, D., Reardon, M., Shabbir, R., Sahoo, S., Hoskin, P., Choudhury, A., Illidge, T. & West, C. M. L., 18 May 2023, In: International Journal of Molecular Sciences. 24, 10, 8956.Research output: Contribution to journal › Article › peer-review
Open Access -
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
Mukherjee, D., Romano, E., Walshaw, R., Zeef, L., Banyard, A., Kitcatt, S., Cheadle, E., Tuomela, K., Pendharkar, S., al-deka, A., salerno, B., Raby, S., Mills, I. G., Honeychurch, J. & Illidge, T., 2023, In: OncoImmunology.Research output: Contribution to journal › Article › peer-review
-
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline
Fox, C. P., Ahearne, M. J., Pettengell, R., Dearden, C. E., El-Sharkawi, D., Kassam, S., Cook, L., Cwynarski, K., Illidge, T. & Collins, G., Feb 2022, In: British Journal of Haematology|B J H. 196, 3, p. 507-522Research output: Contribution to journal › Article › peer-review
Open AccessFile285 Downloads (Pure) -
IRF7 impacts on prostate cancer cell survival in response to radiation
Pickard, A., Amoroso, F., McCulloch, K., Erickson, A., Sachdeva, A., Steele, R., Mukherjee, D., Dellett, M., McComb, J., McCaffery, L., Hart, C. A., Brown, M. D., McDade, S., Waugh, D., Clarke, N., Butterworth, K., Illidge, T., Mirtti, T., Overton, I. M. & Mills, I. G., 23 Sept 2022, In: bioRxiv.Research output: Contribution to journal › Article
-
NIHR Manchester Biomedical Research Centre
Bruce, I. (PI), Lord, G. (CoI), Lennon, R. (CoI), Black, G. (CoI), Wedge, D. (CoI), Morris, A. (CoI), Hussell, T. (CoI), Sharrocks, A. (CoI), Stivaros, S. (CoI), Buch, M. (CoI), Gough, J. (CoI), Kostarelos, K. (CoI), Thistlethwaite, F. (CoI), Kadler, K. (CoI), Barton, A. (CoI), Hyrich, K. (CoI), Mcbeth, J. (CoI), O'Neill, T. (CoI), Vestbo, J. (CoI), Simpson, A. (CoI), Singh, S. (CoI), Smith, J. (CoI), Felton, T. (CoI), Murray, C. (CoI), Griffiths, C. (CoI), Cullum, N. (CoI), Rhodes, L. (CoI), Warren, R. (CoI), Paus, R. (CoI), Dumville, J. (CoI), Viros Usandizaga, A. (CoI), Keavney, B. (CoI), Tomaszewski, M. (CoI), Allan, S. (CoI), Body, R. (CoI), Cartwright, E. (CoI), Heagerty, A. (CoI), Kalra, P. (CoI), Miller, C. (CoI), Rutter, M. (CoI), Smith, C. (CoI), Trafford, A. (CoI), Evans, D. (CoI), Crosbie, E. (CoI), Crosbie, P. (CoI), Harvie, M. (CoI), Howell, S. (CoI), Renehan, A. (CoI), Dive, C. (CoI), Blackhall, F. (CoI), Landers, D. (CoI), Krebs, M. (CoI), Cook, N. (CoI), Clarke, R. (CoI), Taylor, S. (CoI), Jorgensen, C. (CoI), Lorigan, P. (CoI), Jayson, G. (CoI), Valle, J. (CoI), Mccabe, M. (CoI), Armstrong, A. (CoI), Freitas, A. (CoI), Illidge, T. (CoI), Choudhury, A. (CoI), Hoskin, P. (CoI), West, C. (CoI), Van Herk, M. (CoI), Faivre-Finn, C. (CoI), Bristow, R. (CoI), Kirkby, K. (CoI), Birtle, A. (CoI), Mackay, R. (CoI), Radford, J. (CoI), Linton, K. (CoI), Higham, C. (CoI), Munro, K. (CoI), Plack, C. (CoI), Arden Armitage, C. (CoI), Bruce, I. (CoI), Moore, D. (CoI), Saunders, G. (CoI), Stone, M. (CoI), Haddock, G. (CoI), Lewis, S. (CoI), Elliott, R. (CoI), Green, J. (CoI), Lovell, K. (CoI), Morrison, A. (CoI), Shaw, J. (CoI), Bucci, S. (CoI), Ainsworth, J. (CoI), Webb, R. (CoI), Newman, W. (CoI), Banka, S. (CoI), Clayton-Smith, J. (CoI), Payne, K. (CoI), Moldovan, R. (CoI), Wynn, R. (CoI) & Jones, S. (CoI)
1/12/22 → 30/11/27
Project: Research
-
MAnchester RESearch Transforming Radiation Oncology (MAESTRO) Programme as Part of CRUK RadNet.
Bristow, R. (PI), Burnet, N. (CoI), Choudhury, A. (CoI), Dive, C. (CoI), Faivre-Finn, C. (CoI), Hagan, I. (CoI), Hoskin, P. (CoI), Hussell, T. (CoI), Illidge, T. (CoI), Kirkby, K. (CoI), Kostarelos, K. (CoI), O'Connor, J. (CoI), Peek, N. (CoI), Rattray, M. (CoI), Taylor, S. (CoI), Thornton, D. (CoI), Van Herk, M. (CoI), West, C. (CoI), Whetton, A. (CoI), Williams, K. (CoI) & Yorke, J. (CoI)
1/11/19 → 31/10/24
Project: Research
-
Targeting the Akt Pathway with AZD5363 in Combination with Radiotherapy to Improve Tumour Control in Head and Neck Cancer.
Searle, E. (PI), Illidge, T. (CoI), Metcalf, R. (CoI) & Williams, K. (CoI)
1/09/17 → 28/02/21
Project: Research
-
NIHR Biomedical Research Centre: Cancer Precision Medicine Theme.
Dive, C. (PI), Baena Chaparro, E. (CoI), Blackhall, F. (CoI), Bruce, I. (CoI), Bundred, N. (CoI), Carter, L. (CoI), Clarke, R. (CoI), Cook, N. (CoI), Crosbie, P. (CoI), Evans, D. (CoI), Harris, J. (CoI), Hawkins, R. (CoI), Hussell, T. (CoI), Illidge, T. (CoI), Jayson, G. (CoI), Jorgensen, C. (CoI), Kirwan, C. (CoI), Kostarelos, K. (CoI), Krebs, M. (CoI), Lorigan, P. (CoI), Marais, R. (CoI), Marshall, K. (CoI), Metcalf, R. (CoI), Payne, K. (CoI), Radford, J. (CoI), Somervaille, T. (CoI), Springer, C. (CoI), Taylor, S. (CoI), Thistlethwaite, F. (CoI), Viros Usandizaga, A. (CoI) & Zelenay, S. (CoI)
1/04/17 → 31/03/19
Project: Research
-
NIHR Biomedical Research Centre: Cancer Advanced Radiotherapy Theme.
West, C. (PI), Bristow, R. (CoI), Bruce, I. (CoI), Burnet, N. (CoI), Choudhury, A. (CoI), Evans, D. (CoI), Faivre-Finn, C. (CoI), Hoskin, P. (CoI), Illidge, T. (CoI), Kirkby, K. (CoI), Kirkby, N. (CoI), O'Connor, J. (CoI) & Van Herk, M. (CoI)
1/04/17 → 31/03/19
Project: Research
Prizes
-
Fellow of the Academy of Medical Sciences
Illidge, T. (Recipient), 1 Apr 2022
Prize: Fellowship awarded competitively
-
Gold National Clinical Excellence Award
Illidge, T. (Recipient), 2017
Prize: Prize (including medals and awards)
-
NIHR Senior Investigator’s Award
Illidge, T. (Recipient), 2019
Prize: Prize (including medals and awards)
-
Platinum Clinical excellence awards
Illidge, T. (Recipient), 1 Feb 2022
Prize: National/international honour
-
Royal College of Radiologists Gold Medal
Illidge, T. (Recipient), 2018
Prize: Prize (including medals and awards)
Activities
-
Cancer Research UK LTD (External organisation)
Illidge, T. (Academic expert member)
7 Jun 2021 → 8 Jun 2021Activity: Membership › Membership of committee › Research
-
Health and Care Research Wales (External organisation)
Illidge, T. (Academic expert member)
24 May 2021Activity: Membership › Membership of committee › Research
-
Cancer Research UK LTD (External organisation)
Illidge, T. (Academic expert member)
8 Apr 2021 → 9 Apr 2021Activity: Membership › Membership of committee › Research
-
Cancer Research UK LTD (External organisation)
Illidge, T. (Academic expert member)
1 Dec 2020Activity: Membership › Membership of committee › Research
-
Cancer Research UK LTD (External organisation)
Illidge, T. (Academic expert member)
3 Nov 2020 → 4 Nov 2020Activity: Membership › Membership of committee › Research
Impacts
-
Access to more effective therapies in Non-Hodgkin Lymphoma
Illidge, T. (Corresponding participant), Radford, J. (Participant) & Honeychurch, J. (Participant)
Impact: Health and wellbeing, Economic
-
Contribution to rapid international consensus guidelines for radiotherapy treatment during the Covid-19 pandemic to reduce risk to patients and staff
Illidge, T. (Corresponding participant)
Impact: Health and wellbeing
-
Developing radioimmunotherapy into clinical practice- more targeted radiotherapy for lymphoma
Illidge, T. (Corresponding participant)
Impact: Health and wellbeing
-
Improving survival and reducing treatment damage in Hodgkin lymphoma.
Radford, J. (Corresponding participant) & Illidge, T. (Participant)
Impact: Health and wellbeing
-
Seeking treatment for people with recurrent cutaneous T cell lymphoma (CTCL)
Illidge, T. (Corresponding participant)
Impact: Health and wellbeing